Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
Xenetic Biosciences (NASDAQ: XBIO) announced that CEO Jeffrey Eisenberg will present at the Q2 Virtual Investor Summit on May 18, 2021, at 3:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenetic Biosciences (NASDAQ: XBIO) announced that CEO Jeffrey Eisenberg will present at the Q2 Virtual Investor Summit on May 18, 2021, at 3:30 PM ET. The event will include a live video webcast accessible on the company's IR Calendar page and will be archived for 90 days. Xenetic focuses on advancing its XCART™ personalized CAR T platform, targeting patient-specific neoantigens for B-cell lymphomas. The company also leverages its PolyXen® drug delivery platform and holds an exclusive agreement with Takeda Pharmaceuticals.
Details
News Market Reaction – XBIO
The recorded move for XBIO in the trading session of this news was -3.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET
FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present the Q2 Virtual Investor Summit on Tuesday, May 18th at 3:30 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live video webcast of the presentation will be accessible on the IR Calendar page of the Investors section of the Company's website (xeneticbio.com) and will be archived for 90 days following the event.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.
For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/645862/Xenetic-Biosciences-Inc-to-Present-at-the-Q2-Virtual-Investor-Summit
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.